|
|
Volumn 24, Issue 6, 2006, Pages 499-508
|
|
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
a
|
|
Author keywords
Antimetabolite; CS 682; Pharmacokinetic; Phase I
|
|
Indexed keywords
1 BETA DEXTRO ARABINOPENTOFURANOSYLCYTOSINE;
2' CYANO 2' DEOXY 4 N PALMITOYLCYTARABINE;
NUCLEOSIDE ANALOG;
UNCLASSIFIED DRUG;
ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD;
ADULT;
AGED;
ANOREXIA;
AREA UNDER THE CURVE;
ARTICLE;
ASTHENIA;
BLEEDING;
CANCER THERAPY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DIARRHEA;
DRUG HALF LIFE;
DRUG MECHANISM;
FEBRILE NEUTROPENIA;
FEMALE;
FEVER;
HEMATURIA;
HUMAN;
HYPERTENSION;
HYPOTENSION;
MALE;
NAUSEA;
NEUROLOGIC DISEASE;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROTEINURIA;
SOLID TUMOR;
STOMATITIS;
THROMBOCYTOPENIA;
VOMITING;
ADMINISTRATION, ORAL;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTIMETABOLITES, ANTINEOPLASTIC;
ARABINONUCLEOSIDES;
BREAST NEOPLASMS;
COLORECTAL NEOPLASMS;
CYTOSINE;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
LUNG NEOPLASMS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
PRODRUGS;
TREATMENT FAILURE;
TREATMENT OUTCOME;
|
|
EID: 33747690504
PISSN: 01676997
EISSN: None
Source Type: Journal
DOI: 10.1007/s10637-006-8219-0 Document Type: Article |
|
Times cited : (17)
|
|
References (5)
|
